Re: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial

摘要

Technological innovation can provide the opportunity to de-escalate treatments. Oncotype DX is considered a valid tool to promote a reduction in the use of chemotherapy in women with a score indicating intermediate-risk early breast cancer. The TAILORx randomized trial showed noninferiority in terms of long-term outcomes of hormone therapy only vs hormone- and chemotherapy ( ). Mariotto et al. tested the impact of hypothetical testing of early breast cancer in the real world using SEER-Medicare–based data ( ). They showed for the intermediate-risk group a reduction of the burden of chemotherapy in comparison with usual care in the United States.